Seqirus Inc., a leading global player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America, Europe, and Asia-Pacific. Founded in 2015, Seqirus emerged from the merger of Novartis Vaccines and the bioCSL division of CSL Limited, quickly establishing itself as a key innovator in the field of vaccines and immunotherapy. Specialising in the development and production of influenza vaccines, Seqirus is renowned for its cutting-edge technologies and commitment to public health. The company’s unique offerings, such as its adjuvanted flu vaccines, enhance immune responses, making them particularly effective for vulnerable populations. With a strong market position, Seqirus has achieved notable milestones, including significant contributions to pandemic preparedness and a robust portfolio of seasonal flu vaccines, solidifying its reputation as a trusted leader in vaccine innovation.
We don't have data for Seqirus Inc., but we can show you information about their parent organization instead.
View parent company